The company’s latest investment builds on a previous $2.1 million Seed round supported by Defined VC and Old Line Capital Partners. This combined backing provides the resources necessary for Channel Robotics to refine its prototype and navigate the regulatory landscape, with an FDA submission currently targeted for 2027.

Founded by CEO Dr. Philip Weissbrod and co-founder Dr. Michael Yip, the startup aims to shift the landscape of minimally invasive surgery. Their technology bypasses the need for massive, capital-heavy robotic systems by integrating robotic dexterity directly into existing flexible endoscopes. According to the company, this approach is intended to lower the barrier for adoption in ambulatory surgery centers and community practices, making sophisticated procedures more accessible to a broader range of patients.